Arcadia Biosciences Announces Fourth-Quarter and Full-Year 2017 Financial Results and Business Highlights

Error message

Notice: Undefined index: HTTP_USER_AGENT_HTTPS in include_once() (line 581 of /srv/www/arcadiabio.com/public/sites/arcadia/settings.php).

-- Revenues Up, Losses Down, Commercialization Plans Underway for Consumer-Driven Health and Nutrition Ingredient Traits --

DAVIS, Calif. (March 20, 2018) – Arcadia Biosciences, Inc. (Nasdaq: RKDA), a consumer-driven, agricultural food ingredient company, today released its financial and business results for the fourth quarter and full year of 2017.

“2017 was a pivotal year for Arcadia as we sharpened our focus on the commercialization of our non-GM quality and nutrition ingredient traits for the $200B global wheat flour market and demonstrated steady advancement towards the commercialization of our high-value agricultural productivity traits in Argentina and Asia,” said Raj Ketkar, president and CEO. “We achieved notable reductions in our operating loss for the fourth quarter and full year, driven primarily by continued cost containment and the cost efficiencies brought about through focus on a select group of products.

“With the organization in place and commercial launch plans underway in 2018, yesterday we secured $10 million in private equity financing that meaningfully fortifies our cash resources and allows us to effectively execute our health and nutrition growth strategy,” Ketkar said. “This additional financing will accelerate our commercialization activities and demonstrates our commitment to maximizing value for food companies, consumers, growers and our shareholders.”

2017 Operating and Financial Highlights

  • Non-GM Wheat Trait Portfolio. Arcadia advanced its non-GM wheat trait portfolio significantly in 2017 by developing new lines of high fiber Resistant Starch wheat with industry-leading levels of amylose, and identified the phenotype for Reduced Gluten wheat. The company in-licensed CRISPR-Cas9 gene editing technology and began integrating the technology to accelerate current development programs.
  • Strategy. Arcadia validated its strategy to capture value further down the food value chain and built the foundation of a sales and marketing team focused on high-value branded ingredients.
  • GoodWheat™ Brand. As a result of the company’s strategy validation to give consumer packaged goods companies an opportunity to differentiate their brands, Arcadia developed a unique, consumer-facing ingredient brand, GoodWheat™.
  • HB4 Drought Tolerant Soybeans. Arcadia and its Verdeca joint venture partner, Bioceres, advanced HB4 drought tolerant soybeans with the FDA’s requlatory approval of the trait for human food and animal feed. Positive results are anticipated for the 2017 efficacy field trials in South Amercia. Additionally, Arcadia and its partner Mahyco are working to restructure the licenses for our abiotic stress traits for accelerated deregulation.
  • Financial performance. Overall revenues were up for the year and operating expenses were down, resulting in a significant reduction in loss. Operating expenses were down by more than 25 percent from the prior year’s fourth quarter and by more than 15 percent from the prior year, with net loss and net loss attributable to common stockholders down by 20 percent from the prior year. Toward the end of 2017, Arcadia extinguished a costly debt instrument, saving a total of $2 million in cash interest payments over the remaining term of the loan.

2018 Strategic Outlook

  • Executing branded ingredients strategy. In 2018, Arcadia will launch its commercialization plan to become a consumer-driven, branded food ingredient company providing value-added traits to the health and nutrition foods industries.

  • Building commercialization capabilities. Arcadia hired Sarah Reiter as chief commercial officer, with over 20 years of experience in agriculture, to help us migrate forward in the ag-food supply chain, expand our nutrition and health ingredients capabilities and strengthen commercial relationships with consumer food companies.

Arcadia Biosciences, Inc.
Financial Snapshot
(Unaudited)
($ in thousands)

 

Three Months Ended December 31

 

Year Ended December 31

 

2017

2016

% Favorable/

(Unfavorable)

 

2017

2016

% Favorable/

(Unfavorable)

Total Revenues

1,428

540

165%

 

4,026

3,188

26%

Total Operating Expenses

4,427

6,011

26%

 

18,341

21,808

16%

Loss From Operations

(2,999)

(5,471)

45%

 

(14,315)

(18,620)

23%

Net Loss Attributable to Common Stockholders

(2,959)

(5,708)

48%

 

(15,707)

(19,624)

20%

Revenues In the fourth quarter of 2017, revenues were $1.4 million, compared to revenues of $540,000 in the fourth quarter of 2016. For annual 2017, overall revenues increased to $4.0 million compared to $3.2 million during the same period of 2016. The quarter-over-quarter and annual results were primarily impacted by previously deferred upfront license fees recognized as several agreements were discontinued in the fourth quarter of 2017, as well as delays identified in the fourth quarter of 2016 to the estimated commercial launch dates within the portfolio of license agreements.

Operating Expenses In the fourth quarter of 2017, operating expenses were $4.4 million, compared to $6.0 million in the fourth quarter of 2016. For annual 2017, operating expenses were $18.3 million, compared to $21.8 million during the same period in 2016. Annual research and development (R&D) spending decreased by $1.3 million in 2017 and general and administrative (SG&A) decreased by $1.6 million. Both expense categories had decreases driven primarily by lower salaries and benefits, mainly the result of workforce reductions made during the latter part of 2016. Cost of product revenues deceased by $612,000 as 2016 included a write-down of inventory and none was recorded in 2017.

Net Loss Attrituable to Common Stockholders Net loss attributable to common stockholders for the fourth quarter of 2017 was $3.0 million, or a loss of $1.39 per share, a 48 percent improvement from the $5.7 million loss in the fourth quarter of 2016. Net loss attributable to common stockholders for the year was $15.7 million, or a loss of $7.28 per share, a 20 percent improvement from the $19.6 million loss in 2016. 

The net loss attributable to common stockholders in the fourth quarter of 2016 included interest expense on the term loan that was paid off in the third quarter of 2017. The annual loss for 2017 includes a non-recurring loss on extinghishment of debt in the amount of $900,000, as well as interest expense through the date of payoff. 

Conference Call and Webcast The company has scheduled a conference call for 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss fourth-quarter and annual results and key strategic achievements.

Interested participants can join the conference call using the following numbers:

U.S. Toll-Free Dial-In: +1-844-243-4690 International Dial-In: +1-225-283-0138 Passcode: 7664338

A live webcast of the conference call will be available on the “Investors” section of the Arcadia’s website at <www.arcadiabio.com>. Following completion of the call, a recorded replay will be available on the company’s investor website.

Safe Harbor Statement “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to components of the company’s long-term financial success and ongoing plans; the company’s traits, commercial products, and collaborations; and the company’s ability to manage the regulatory processes for its traits and commercial products. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s and its partners’ ability to develop commercial products incorporating its traits and to complete the regulatory review process for such products; the company’s compliance with laws and regulations that impact the company’s business, and changes to such laws and regulations; and the company’s future capital requirements and ability to satisfy its capital needs. Further information regarding these and other factors that could affect the company’s financial results is included in filings the company makes with the Securities and Exchange Commission from time to time, including the section entitled “Risk Factors” in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 and additional information that will be set forth in its Form 10-K for the year ended December 31, 2017. These documents are or will be available on the SEC Filings section of the Investor Relations pages of the company’s website at <www.arcadiabio.com>. All information provided in this release and in the attachments is as of the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to update this information.

About Arcadia Biosciences, Inc. Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops agricultural products that create added value for farmers, enhance human health and improve the environmental sustainability of agriculture. Arcadia’s nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. Arcadia’s agronomic performance traits are aimed at making agricultural production more economically efficient and environmentally sound. For more information, visit <www.arcadiabio.com>

Arcadia Biosciences, Inc.
Consolidated Balance Sheets
(Unaudited)
(In thousands, except share data)

 

As of December 31,

 

 

2017

 

 

2016

 

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

$

9,125

 

 

$

2,013

 

Short-term investments

 

3,898

 

 

 

48,547

 

Accounts receivable

 

1,231

 

 

 

349

 

Unbilled revenue

 

4

 

 

 

184

 

Inventories — current

 

229

 

 

 

252

 

Prepaid expenses and other current assets

 

560

 

 

 

877

 

Total current assets

 

15,047

 

 

 

52,222

 

Property and equipment, net

 

299

 

 

 

508

 

Inventories — noncurrent

 

1,168

 

 

 

1,327

 

Long-term investments

 

 

 

 

2,498

 

Other noncurrent assets

 

56

 

 

 

19

 

Total assets

$

16,570

 

 

$

56,574

 

Liabilities and stockholdersÕ equity

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable and accrued expenses

$

2,496

 

 

$

2,359

 

Amounts due to related parties

 

29

 

 

 

30

 

Unearned revenue — current

 

1,000

 

 

 

740

 

Total current liabilities

 

3,525

 

 

 

3,129

 

Notes payable

 

 

 

 

25,127

 

Unearned revenue — noncurrent

 

2,038

 

 

 

3,120

 

Other noncurrent liabilities

 

3,000

 

 

 

3,000

 

Total liabilities

 

8,563

 

 

 

34,376

 

StockholdersÕ equity:

 

 

 

 

 

 

 

Common stock, $0.001 par value—150,000,000 and 400,000 shares

  authorized as of December 31, 2017 and December 31, 2016; 2,134,154

  and 2,224,384 shares issued and outstanding as of December 31, 2017

  and December 31, 2016, respectively

 

42

 

 

 

44

 

Additional paid-in capital

 

175,223

 

 

 

173,723

 

Accumulated deficit

 

(167,257

)

 

 

(151,550

)

Accumulated other comprehensive loss

 

(1

)

 

 

(19

)

Total stockholdersÕ equity

 

8,007

 

 

 

22,198

 

Total liabilities and stockholdersÕ equity

$

16,570

 

 

$

56,574

 

Arcadia Biosciences, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except share and per share data)

 

Year Ended December 31,

 

 

2017

 

 

2016

 

Revenues:

 

 

 

 

 

 

 

Product

$

514

 

 

$

669

 

License

 

1,470

 

 

 

144

 

Contract research and government grants

 

2,042

 

 

 

2,375

 

Total revenues

 

4,026

 

 

 

3,188

 

Operating expenses:

 

 

 

 

 

 

 

Cost of product revenues

 

283

 

 

 

895

 

Research and development

 

7,407

 

 

 

8,663

 

Selling, general and administrative

 

10,651

 

 

 

12,250

 

Total operating expenses

 

18,341

 

 

 

21,808

 

Loss from operations

 

(14,315

)

 

 

(18,620

)

Interest expense

 

(747

)

 

 

(1,319

)

Other income, net

 

281

 

 

 

340

 

Loss on extinguishment of debt

 

(900

)

 

 

 

Net loss before income taxes

 

(15,681

)

 

 

(19,599

)

Income tax provision

 

(26

)

 

 

(25

)

Net loss attributable to common stockholders

$

(15,707

)

 

$

(19,624

)

Net loss per share attributable to common stockholders:

 

 

 

 

 

 

 

Basic and diluted

$

(7.28

)

 

$

(8.85

)

Weighted-average number of shares used in per share

   calculations:

 

 

 

 

 

 

 

Basic and diluted

 

2,156,201

 

 

 

2,218,341

 

Other comprehensive income, net of tax

 

 

 

 

 

 

 

Unrealized gains on available-for-sale securities

 

18

 

 

 

96

 

Other comprehensive income

 

18

 

 

 

96

 

Comprehensive loss attributable to common stockholders

$

(15,689

)

 

$

(19,528

)

Arcadia Biosciences, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)

 

Year Ended December 31,

 

 

2017

 

 

2016

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

Net loss

$

(15,707

)

 

$

(19,624

)

Adjustments to reconcile net loss to cash used in operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

279

 

 

 

304

 

(Gain) Loss on disposal of equipment

 

(1

)

 

 

4

 

Net amortization of investment premium and discount

 

(89

)

 

 

140

 

Loss on sale of investments

 

2

 

 

 

 

Stock-based compensation

 

1,474

 

 

 

1,059

 

Accretion of debt discount

 

98

 

 

 

198

 

Loss on extinguishment of debt

 

900

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts receivable

 

(882

)

 

 

357

 

Unbilled revenue

 

179

 

 

 

(102

)

Inventories

 

183

 

 

 

582

 

Prepaid expenses and other current assets

 

324

 

 

 

(185

)

Other noncurrent assets

 

11

 

 

 

5

 

Accounts payable and accrued expenses

 

87

 

 

 

(19

)

Amounts due to related parties

 

(1

)

 

 

11

 

Unearned revenue

 

(822

)

 

 

215

 

Net cash used in operating activities

 

(13,965

)

 

 

(17,055

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

Proceeds from sale of property and equipment

 

4

 

 

 

 

Purchases of property and equipment

 

(79

)

 

 

(231

)

Purchases of investments

 

(19,405

)

 

 

(41,385

)

Proceeds from sales and maturities of investments

 

66,658

 

 

 

36,315

 

Net cash provided by (used in) investing activities

 

47,178

 

 

 

(5,301

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

Payments of debt issuance costs

 

 

 

 

(46

)

Payments of debt extinguishment costs

 

(1,125

)

 

 

 

Payments on notes payable

 

(25,000

)

 

 

 

Proceeds from exercise of stock options and purchases through ESPP

 

24

 

 

 

442

 

Net cash (used in) provided by financing activities

 

(26,101

)

 

 

396

 

Net increase (decrease) in cash and cash equivalents

 

7,112

 

 

 

(21,960

)

Cash and cash equivalents — beginning of period

 

2,013

 

 

 

23,973

 

Cash and cash equivalents — end of period

$

9,125

 

 

$

2,013

 

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

 

 

 

 

 

 

 

Cash paid for interest

$

746

 

 

$

1,033

 

Cash paid for income taxes

$

2

 

 

$

29

 

NONCASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

 

Exchange of membership interest in unconsolidated entity for common stock

$

2

 

 

$

 

Proceeds from sale of fixed assets included in prepaid expenses and other current assets

$

7

 

 

$

 

Deferred financing costs in accounts payable and accrued expenses

$

50

 

 

$